- Multiple Sclerosis Relapses Following Cessation of Fingolimod2022 | First Faculty of Medicine
- Treatment of relapsing-remitting multiple sclerosis2008 | First Faculty of Medicine
- Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod2018 | First Faculty of Medicine
- COVID-19 vaccination and relapse activity: A nationwide cohort study of patients with multiple sclerosis in Denmark2024 | First Faculty of Medicine
- Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosis-related Hospitalizations : Integrated Analysis of the Delayed-release Dimethyl Fumarate Phase III Studies2015 | First Faculty of Medicine
- Ocrelizumab in the treatment of multiple sclerosis - view of a neurologist and immunologist2018 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Innate Immune System and Multiple Sclerosis. Granulocyte Numbers Are Reduced in Patients Affected by Relapsing-Remitting Multiple Sclerosis during the Remission Phase2020 | Second Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis2023 | First Faculty of Medicine
- Pregnancy and multiple sclerosis2010 | Second Faculty of Medicine
- Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison2014 | First Faculty of Medicine
- Effect of BG-12 on contrast-enhanced lesions in patients with relapsing-remitting multiple sclerosis: subgroup analyses from the phase 2b study2012 | Second Faculty of Medicine
- Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis2015 | First Faculty of Medicine
- Comparison of Pharmacological Therapies in Relapse Rates in Patients With Relapsing-Remitting Multiple Sclerosis2023 | Faculty of Physical Education and Sport
- Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis2023 | First Faculty of Medicine, Third Faculty of Medicine
- Is breastfeeding in MS harmful or not? An answer from real-world Czech data2023 | First Faculty of Medicine, Second Faculty of Medicine, Faculty of Medicine in Hradec Králové, Faculty of Medicine in Pilsen, Third Faculty of Medicine
- Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study2010 | First Faculty of Medicine
- Analysis of the Group of Pediatric Patients With Relapsing-Remitting Multiple Sclerosis: Data From the Czech National Registry2022 | Second Faculty of Medicine, Faculty of Medicine in Pilsen, Third Faculty of Medicine
- Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study2014 | First Faculty of Medicine
- Paediatric onset of multiple sclerosis: Analysis of chemokine and cytokine levels in the context of the early clinical course2020 | Second Faculty of Medicine
- Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS2012 | First Faculty of Medicine
- Interferon beta-1a vs. glatiramer acetate: changes of innate immunity in a group of women with multiple sclerosis2023 | Faculty of Medicine in Hradec Králové, Faculty of Medicine in Pilsen
- Effect of BG-12 on contrast-enhanced lesions in patients with relapsing-remitting multiple sclerosis: subgroup analyses from the phase 2b study2012 | First Faculty of Medicine
- ECTRIMS/ACTRIMS 2017 - News in research and treatment of Multiple Sclerosis2017 | Publication without faculty affiliation
- A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis: results from the MSBase registry2023 | First Faculty of Medicine
- Long-term safety and efficacy of daclizumab beta in relapsing-remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study2020 | First Faculty of Medicine
- Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis : A Subgroup Analysis From Three International Cohorts2021 | First Faculty of Medicine
- Association of Sustained Immunotherapy With Disability Outcomes in Patients With Active Secondary Progressive Multiple Sclerosis2020 | First Faculty of Medicine